Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer

Author:

Maksymiuk Andrew W12,Tappia Paramjit S3,Sitar Daniel S24,Akhtar Parveen S5,Khatun Nazrina5,Parveen Rahnuma5,Ahmed Rashiduzzaman6,Ahmed Rashid Bux7,Cheng Brian7,Huang Gina7,Bach Horacio8,Hiebert Brett9,Ramjiawan Bram34

Affiliation:

1. Cancer Care Manitoba, Winnipeg, MB, R3E 0V9, Canada

2. Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, R3A 1R9, Canada

3. Clinical Research Institute & Office of Clinical Research, St Boniface Hospital, Winnipeg, MB, R2H 2A6, Canada

4. Department of Pharmacology & Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, R3E 0T5, Canada

5. Department of Medical Oncology, National Institute of Cancer Research & Hospital, Mohakhali, Dhaka, Bangladesh

6. FastBios, Dhaka, Bangladesh

7. BioMark Diagnostics Inc., Richmond, BC, V6X 2W8, Canada

8. Division of Infectious Diseases, Faculty of Medicine, University of British Columbia, Vancouver, BC, V5Z 3J5, Canada

9. Cardiac Sciences Program, Asper Clinical Research Institute, Winnipeg, MB, R2H 2A6, Canada

Abstract

Aim: Spermidine/spermine N1-acetyltransferase (SSAT-1) plays a critical role in cell growth, proliferation and death, and is known to be activated in human cancer cells. Amantadine, a US FDA-approved antiviral drug, is a substrate for SSAT-1 and can be used to indirectly measure SSAT-1 activity because of its conversion to acetylamantadine (AA). This study was undertaken to further validate SSAT-1 activity in breast and lung cancer patients. Results: An increase in the urinary concentration of AA in lung and breast cancer patients was observed. The 0–2 h collection time point was determined to be optimal in revealing significant differences in urinary AA concentration between healthy controls and cancer patients. Conclusion: The high urine concentration of AA could be used as a simple and useful test for the detection of breast and lung cancer.

Publisher

Future Science Ltd

Subject

Biotechnology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3